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Extensive  use  of  Vaccinia  virus  (VACV)  in  research  has  led  to  associated  accidental  human  exposure
in  laboratories  worldwide.  In  spite  of  the  social  and  economic  relevance  of  Bovine  Vaccinia  outbreaks
in  Brazil,  national  data  concerning  laboratory  workers  handling  these  infectious  agents  are  relativelyccepted 9 August 2013
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scarce.  Therefore,  a  serological  survey  was  conducted  in  a Brazilian  laboratory  to evaluate  staff  exposure
to orthopoxviruses  (OPVs).  Information  concerning  direct  work  with  OPVs,  vaccination  status  and  labo-
ratory  accidents  was  collected  and  correlated  to  serology  results.  This  study  presents  an  opportunity  for
discussion  of  routine  procedures  involving  OPVs  in  laboratories  and  their  intrinsic  risks.  Aspects  of  the
live  attenuated  smallpox  vaccine  are  also  discussed.erological survey
The family Poxviridae includes a group of pathogens capable of
nfecting a variety of organisms. It is segregated into two subfam-
lies: Entomopoxvirinae,  represented by invertebrate viruses, and
hordopoxvirinae, with viruses that infect vertebrates. Among the
enera of the subfamily Chordopoxvirinae,  the Orthopoxvirus (OPV)
raws attention to species like Variola virus (VARV), already erad-
cated; Monkeypox virus (MPXV), endemic in Africa and Cowpox
irus (CPXV) which has been associated to several human and ani-
al  cases in Europe recently. All of these viruses are capable of
igniﬁcant impact on global public health [1,2].
VARV was the etiological agent of smallpox, an exanthematic
isease of high morbidity and lethality. Although smallpox was
eclared erradicated in 1980, this status was only achieved after a
lobal vaccination program conducted by the World Health Orga-
ization (WHO). Vaccinia virus (VACV) was used as a vaccine and it
ucceeded in producing protective immunity against smallpox due
o cross antigenicity observed among OPV’s species [1,3–5].
After smallpox eradication in 1980, mass vaccination was  glob-
lly interrupted. The possibility of VARV use as a bioweapon
otivated the United States of America (USA) to reestablish vacci-
ation for military forces and health care professionals. The growth
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of research related to OPV posed another concern and vaccination
of laboratory workers is nowadays highly recommended in science
centers of the USA and Europe [6–8].
Despite vaccination and speciﬁc biosecurity levels to manip-
ulate OPVs, occupational infections in laboratories have been
reported recently. These accidents usually involve direct con-
tact during manipulation of contaminated sharp edge material.
Mucosal exposure to contaminated aerosols is also a risk, espe-
cially when VACV infected animals or tissue cultures are involved.
Vaccine wounds are also sources of infection as observed in cases
of eczema vaccinatum and vaccinia necrosum described in US
recently. Although frequently related to accidents among the USA
military community, vaccinated scientists are also a risk to naïve
individuals [9–16].
The natural circulation of VACV has been reported in Brazil
since 1999, associated with a zoonosis called Bovine Vaccinia (BV).
BV affects dairy cattle and those who work directly with bovines,
either through milking procedures or veterinary health. Transmis-
sion occurs after the contact of bare hands with VACV lesions on
the teats of infected cows [17]. Two atypical outbreaks involv-
ing equines were reported in 2009 and 2012 [18, LOBATO, 2012
– unpublished]. The source of infection is yet to be established as
VACV infected cattle wasn’t present in neither episode.
The signiﬁcant social and economic impact of BV on rural
areas of Brazil has inspired several VACV studies in the country.
For instance, laboratories may  isolate VACV from ﬁeld samples,
examine the biologic and molecular characterization of the virus,
investigate the epidemiology of outbreaks, etc. [19–23]. National
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esearch on VACV also concerns recombinant vaccines, cytology
nd oncology, following the current global trend.
This survey was conducted in a laboratory known for its work
ith VACV and other OPVs for several years. The objective was to
etermine staff exposure to OPV and correlate serological results
ith variables that might reveal unknown risks or conﬁrm expected
nes. Fifty workers among undergraduate, master’s and PhD stu-
ents, professors and technicians volunteered themselves to be
art of the study. This study was approved by the Research Ethics
ommittee of UFMG under the registration protocol FR-413704.
Whole blood (in the absence of anticoagulants) was  collected
rom all volunteers. To assess immunological data, a plaque reduc-
ion neutralizing test (PRNT) [24] was chosen, as it represents the
old standard for verifying the presence of neutralizing anti-OPV
ntibodies. Furthermore, neutralizing antibodies are extremely
elated to protective immunity against OPV(s). Sera were ini-
ially heated in a water bath at 56 ◦C for 30 min  to denature
omplement system proteins and subsequently diluted in Eagle’s
inimum Essential Medium (MEM)  free of fetal bovine sera (FBS) to
 screening ratio of 1:20. Samples were added to the same volume
1:1) of a solution containing approximately 150 plaque forming
nits (PFU) of VACV strain Western Reserve (WR) diluted in FBS-
ree MEM.  The ﬁnal solution (virus/serum) was homogenized and
ncubated for 16 h at 37 ◦C.
Six-well plates containing BSC-40 monolayers with approx-
mately 90% of conﬂuence were inoculated with virus/serum
olution; plates were incubated at 37 ◦C for 1 h in an atmosphere
upplemented with 5% of CO2. MEM  supplemented with 2% FBS was
dded to each well in a volume sufﬁcient to maintain cell mono-
ayers during the subsequent incubation period of 48 h at 37 ◦C
n atmosphere supplemented with 5% of CO2. BSC-40 monolayers
ere ﬁxed with formalin at 10% and stained with crystal violet
olution at 1% allowing naked eye observation of cytopathic effects.
All samples were tested in triplicate. A sample was  considered
ositive when the average number of PFUs was lower than half the
FUs counted in the virus control (at least a 50% reduction in PFUs).
he virus control (VC), also known as the negative serum control,
as represented by using only FBS; it was treated as a regular serum
ample and submitted to the same protocol. Each six-well plate
ncluded one well reserved for the VC and one for cell control (a
egative control). Furthermore, a positive control was  included by
mploying a human serum sample obtained during a VB outbreak.
All positive samples were titrated according to the PRNT pro-
ocol described above, with the exception of the two fold serial
ilution of the sera. The last dilution in which 50% PFU reduction
as observed was used as a reference to calculate the value of neu-
ralizing units per milliliter. The value was obtained by dividing
 mL  by the volume of virus/serum solution inoculated and multi-
lying it by the last positive dilution value.
All volunteers were submitted to a questionnaire to obtain epi-
emiological information. These data were converted to variables
nd related to the presence or absence of neutralizing anti-OPV
ntibodies. Results were considered statistically signiﬁcant when
he Fisher’s exact test resulted in a P value ≤0.05. Statistical analyses
ere performed using the program Open-Epi v.2.3.1.
General characteristics of the cohort are shown in Table 1. Age
anges from 19 to 70 years old. A majority of volunteers are women
64%). Graduate students represent 46%, with ﬁfteen undergradu-
te students, seven technicians and ﬁve professors.
At a glance, nine PRNT50 seropositive individuals (18%) are
bserved. Statistical analysis demonstrated that individuals who
ave worked in the laboratory for less than ten years are more
ikely not to have neutralizing anti-OPV antibodies than those
ho have worked over ten years (OR = 15.6, CI% = 2.3–108). A
ossible explanation could be the longer period of time these
ndividuals have been exposed to an environment where OPVs are (2013) 4706– 4709 4707
manipulated. As showed in Table 3, experience time in laboratory
is also statistically signiﬁcant when compared with smallpox
vaccination (P < 0.000). However, we  cannot exclude the possibil-
ity of accidental imperceptible contamination within this group,
working as a boost to the maintenance of immune response.
Moreover, biosafety issues have changed much in the past decade.
The increased use of personal protection equipment (PPE) and
related technologies may  be responsible for the greater number of
seronegative individuals among recent workers.
As observed in Table 2, previous history of smallpox vaccination
is signiﬁcantly related to the presence of neutralizing antibodies
(OR = 5.4, CI% = 283.9). Table 2, aditionally, demonstrates vaccinated
individuals with antibody titers ranging from 200 to 800 NU/mL,
a much smaller range compared to those of accidentally exposed
individuals (from 200 to ≥6400 NU/mL). This disparity may  reﬂect
the exposure dose or time elapsed since the exposure (accidental
or vaccine). One seropositive individual injured had your ocular
mucosa exposed, and 2 individuals had their oral mucosa, all of
them with diluted virus solution. Accidents occurred in 1987 with
one seropositive individual and in 2010 with two. Older accident
could be related to insufﬁcient laboratory protection in that time.
This individual reported fever, lymphadenopathy and lesion devel-
opment. Recent accidents are associated to the neglected use of
PPE. Other seronegative individuals had similar accidents, except
one, that was bitten by a VACV infected guinea pig.
It is known that all seropositive vaccinated individuals were
vaccinated before 1980 during smallpox eradication campaign. The
long-term immunity conferred by smallpox vaccination is related
to neutralizing antibodies, which are correlated with protective
immunity [25–28] and is observed among six of eight immunized
subjects. The two  vaccinated but seronegative individuals were
immunized less than ﬁfteen years ago with the Dryvax vaccine;
neither presented the characteristic lesion produced on the left
arm after VACV inoculation. A smallpox vaccine scar however, was
observed in only four of the six seropositive vaccinated individuals.
Accidents during OPV manipulation are not statistically a risk
when OPV exposure is evaluated through PRNT. Although it sug-
gests the rules imposed by this biosecurity level 2 laboratory are
effective, one cannot disregard the three individuals who became
seropositive after accidents. It is important to evaluate the cohort
statistically, but in this speciﬁc situation the event itself matters as
much as a low P value. Two  of the seropositive individuals described
systemic nonspeciﬁc symptoms after OPV exposure. As evidenced
by their high titers, they may  have been more than exposed, but
productively infected.
In this question, it is also important to consider OPV exposition
in ﬁeld works. Though individuals use recommended biosafety pro-
tocols and PPE, they deal with unknown viral load in sick animals
and people, beyond wild environment with potentials unknown
hosts.
VACV productive infection in laboratory workers may  gener-
ate economic and public health onus [12]. When the amount of
research involving mutant OPV based vaccines and oncolytic agents
are considered, responsibility far beyond what is currently man-
aged may  emerge. Infected individuals easily spread virus to the
environment through the inoculation site and possible recombi-
nation among different VACV may  generate unexpected mutants
or reversion to virulence of initially attenuated strains. Any unin-
tended transmission event should be avoided, even though the risk
applies to a small number of individuals. Epidemiology has proven
that a single infected human is all it takes to spark a severe out-
break involving several dairy properties and hundreds of human
and bovine hosts in Brazil [17–20,22,23].
In Brazil there are no data concerning the number of researchers
working with OPVs. National education regarding the natural circu-
lation of VACV among dairy cattle is exclusive to small speciﬁc VACV
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Table 1
Serology related to demographic variables.
Variables Tested individuals, n (%)a PRNT positive individuals, n (%) PRNT negative individuals, n (%) P valueb
Age
<26 years 29 (58) 1 (4.8) 21 (72.4) 0.06
≥26  years 21 (42) 8 (27.6) 20 (95.2)
Gender
Female 32 (64) 6 (18.8) 26 (81.2) 1.00
Male  18 (36) 3 (16.7) 15 (83.3)
Occupation
Professor 5 (10) 2 (40) 3 (60) 0.334
Technician 7 (14) 1 (14.3) 6 (85.7)
Graduate studentc 23 (46) 5 (21.8) 18 (78.2)
Undergraduate student 15 (30) 1 (6.7) 14 (93.3)
Experience in the laboratory
<10 years 44 (88) 5 (11.4) 39 (88.6) 0.007
≥10  years 6 (12) 4 (66.7) 2 (33.3)
Total 50 (100) 9 (18) 41 (82) –
a The % represents frequency of tested individuals per category.
b Fisher’s exact test.
c In Brazil this group includes master’s, doctoral and post-doctoral students.
Table 2
Serology related to OPV possible exposure events.
Variables Tested individuals,
n (%)a
PRNT positive
individuals, n (%)
P valueb Seropositive individuals
ID Exposure event PRNT50 titer (NU/mL)c
Works with OPV
Yes 30 (60) 7 (77.8) 0.285 1 Smallpox vaccine 400
No  20 (40) 2 (22.2)
Contact with OPV contaminated material 2 Smallpox vaccine 400
Yes  34 (68) 7 (77.8) 0.699 3 Unknown ≥6400
No  16 (32) 2 (22.2)
Accident during OPV manipulation 4 Laboratory accident ≥6400
Yes  9 (18) 3 (33.3) 0.334 5 Smallpox vaccine &
laboratory accident
200
No  41 (82) 6 (66.7)
Contact with BV outbreaks 6 Smallpox vaccine 400
Yes  12 (24) 3 (33.3) 0.668 7 Laboratory accident 800
No  38 (76) 6 (66.7)
Smallpox vaccination history 8 Smallpox vaccine 800
Yes  8 (16) 6 (66.7) <0.000 9 Smallpox vaccine 400
No  42 (84) 3 (33.3)
Total 50 (100) 9 (100) – – – –
a % for tested individuals is represented by category and % for PRNT positive individuals is represented by rows.
b Fisher’s exact test.
c Neutralizing units.
Table 3
Smallpox vaccination history related to others OPV possible exposure eventsa.
Variables Tested individuals, n (%) PRNT positive individuals, n (%) Smallpox vaccination history, n (%)b P valuec
Works with OPV
Yes 30 (60) 7 (77.8) 7 (87.5) 0.123
No  20 (40) 2 (22.2) 1 (12.5)
Contact with OPV contaminated material
Yes 34 (68) 7 (77.8) 7 (87.5) 0.409
No  16 (32) 2 (22.2) 1 (12.5)
Accident during OPV manipulation
Yes 09 (18) 3 (33.3) 2 (25) 0.623
No  41 (82) 6 (66.7) 6 (75)
Contact with BV outbreaks
Yes 12 (24) 3 (33.3) 4 (50) 0.082
No  38 (76) 6 (66.7) 4 (50)
Experience in the laboratory
<10 years 44 (88) 5 (55.6) 6 (75) <0.000
≥10  years 6 (12) 4 (44.4) 2 (25)
Total  50 (100) 9 (100) 8 (100) –
a All % represents frequency of tested individuals per category.
b Column four refers to total number of individuals indicated in column two.
c Fisher’s exact test. Just related between variables and vaccinated individuals.
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ndemic areas and speciﬁc health care professionals. Although the
se of live attenuated VACV vaccines is controversial, it still rep-
esents the best available prophylaxis, as observed in USA where
econd generation ACAM2000TM vaccine is successfully used. New
eneration vaccine, Modiﬁed Vaccinia Ankara (MVA), associated
o mild adverse effects in mammal’s cells, also poses as a strong
andidate although it is still on clinical trial [5]. Nevertheless, no
istribution policy occurs in places other than the USA and Europe.
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